These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 16677089)

  • 1. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
    Lodi R; Tonon C; Calabrese V; Schapira AH
    Antioxid Redox Signal; 2006; 8(3-4):438-43. PubMed ID: 16677089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
    Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial dysfunction in friedreich's ataxia.
    Lodi R; Taylor DJ; Schapira AH
    Biol Signals Recept; 2001; 10(3-4):263-70. PubMed ID: 11351132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review).
    Palau F
    Int J Mol Med; 2001 Jun; 7(6):581-9. PubMed ID: 11351269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
    Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
    Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
    Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
    Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Friedreich ataxia: an update on animal models, frataxin function and therapies.
    González-Cabo P; Llorens JV; Palau F; Moltó MD
    Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia.
    Rötig A; de Lonlay P; Chretien D; Foury F; Koenig M; Sidi D; Munnich A; Rustin P
    Nat Genet; 1997 Oct; 17(2):215-7. PubMed ID: 9326946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial damage and senescence phenotype of cells derived from a novel frataxin G127V point mutation mouse model of Friedreich's ataxia.
    Fil D; Chacko BK; Conley R; Ouyang X; Zhang J; Darley-Usmar VM; Zuberi AR; Lutz CM; Napierala M; Napierala JS
    Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32586831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich's ataxia'.
    Abeti R; Parkinson MH; Hargreaves IP; Angelova PR; Sandi C; Pook MA; Giunti P; Abramov AY
    Cell Death Dis; 2016 May; 7(5):e2237. PubMed ID: 27228352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Friedreich's ataxia.
    Alper G; Narayanan V
    Pediatr Neurol; 2003 May; 28(5):335-41. PubMed ID: 12878293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
    Cooper JM; Schapira AH
    Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Friedreich's ataxia: past, present and future.
    Marmolino D
    Brain Res Rev; 2011 Jun; 67(1-2):311-30. PubMed ID: 21550666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
    Cooper JM; Schapira AH
    Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.
    Lodi R; Cooper JM; Bradley JL; Manners D; Styles P; Taylor DJ; Schapira AH
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11492-5. PubMed ID: 10500204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GAA-repeat-expansion-based mouse model of Friedreich's ataxia.
    Anjomani Virmouni S; Ezzatizadeh V; Sandi C; Sandi M; Al-Mahdawi S; Chutake Y; Pook MA
    Dis Model Mech; 2015 Mar; 8(3):225-35. PubMed ID: 25681319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia.
    Abeti R; Uzun E; Renganathan I; Honda T; Pook MA; Giunti P
    Pharmacol Res; 2015 Sep; 99():344-50. PubMed ID: 26141703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Friedreich's ataxia: clinical aspects and pathogenesis.
    Pandolfo M
    Semin Neurol; 1999; 19(3):311-21. PubMed ID: 12194387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
    Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
    Marmolino D; Acquaviva F
    Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.